BHVN (Biohaven Corp) Market Value to Book Value Ratio
Current price action for Biohaven Ltd. (BHVN) reflects the current 182.67 metric. The lack of market influence on prices is driven by massive investments in medical trials. The business relies on unique methods for combating abnormal proteins and ion channels. Supply stability is ensured by an extensive network of plants and strict logistics control, which guarantees high operational margins.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_BHVN_-_Biohaven-Ltd._-_Capitalization-to-Book-Value-Ratio "BHVN Biohaven Market Capitalization to Book Value Ratio (07/04/2022 - 10/27/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Biohaven Ltd (BHVN)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:Biohaven Ltd.
For an investor, assessing the asset quality of Biohaven Ltd. (BHVN) requires an analysis of the market value premium over net assets. By analyzing the market valuation of book capitalization, we measure the equity revaluation ratio, which for this pharmaceutical company directly reflects market expectations regarding the success of clinical trials and future patent protection for innovative drugs, thereby determining the fair value of the business.
Competitor analysis
Market Value to Book Value Ratio Biogen Inc.|NBIX (neurocrine.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Amylyx Corp (AMLX) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Trevi Therapeutics|Market Value to Book Value Ratio praxismedicines.com|AVXL (Anavex Life Sciences Corp.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value CBLL (CeriBell Inc)|PRTA: Market Value to Book Value Ratio|Market-to-Book Ratio Alector Inc. ALEC|Market Capitalization to Book Value Ratio Annexon, Inc. (ANNX)|OMER - Market Value to Book Value|NGNE: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio AC Immune S.A.|Market Cap to Net Assets Ratio Voyager Pharma|Market Value to Book Value Ratio Neumora Corp|Scilex Holding Company - Market Capitalization to Book Value Ratio|Market-to-Book Ratio TVGN (tevogen.com)|ACOG - Market Value to Book Value Ratio|CGTX - Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Inhibikase (IKT)|SAVA: Market Value to Book Value|assertiotx.com (ASRT) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Coya Therapeutics|VistaGen Therapeutics, Inc. (VTGN) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple Ovid Rx|Market Capitalization to Book Value Ratio Acumen Pharma ABOS|Capitalization to Book Value Ratio CervoMed Corporation CRVO|Market Cap to Net Assets Ratio ATHE|Market Capitalization to Book Value Clene Inc CLNN|PEPG - Market Capitalization to Book Value Ratio|JUNS - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio Relmada RLMD|Market Value to Book Value Annovis Bio Corporation|Market Cap to Net Assets Ratio Grace Therapeutics Inc|Market Value to Book Value Ratio AIFF|Market Value to Book Value Ratio Klotho Neurosciences Inc KLTO|Capitalization to Book Value Ratio NRSN (neurosense-tx.com)|RVPH - Market Value to Book Value Ratio|Capitalization to Book Value Ratio MetaVia Inc. MTVA|NRXS (NeurAxis, Inc.) - Market Capitalization to Book Value Ratio|Helius Medical (HSDT) - Market-to-Book Ratio|PASG: Market Cap to Net Assets Ratio|NEUP (Neuphoria Therapeutics) - Market Capitalization to Book Value Ratio|NERV - Market Value to Book Value Ratio|Market Value to Book Value ATHA|Addex Therapeutics - Market Value to Book Value Ratio|Market-to-Book Ratio alzamend.com (ALZN)|Market Capitalization to Book Value Ratio Cyclerion Therapeutics, Inc. CYCN|Market Value to Book Value Ratio Protagenic Therapeutics Inc. PTIX|Market Capitalization to Book Value Ratio KTTA (Pasithea)|CRGT: Market Capitalization to Book Value|Market Value to Book Value Ratio ATXI|brainstorm-cell.com (BCLI) - Market-to-Book Ratio|CARA - Market Capitalization to Book Value Ratio|Market Value to Book Value Chromocell Therapeutics Corp|Market Capitalization to Book Value Ratio ELYM|Market Capitalization to Book Value Ratio intracellulartherapies.com ITCI|Market Cap to Net Assets Ratio Longboard Pharmaceuticals LBPH|Market Value to Book Value Ratio marinuspharma.com MRNS|NKGN (NKGen Biotech) - Market Capitalization to Book Value Ratio|NRBO: Market-to-Book Ratio|Market Value to Book Value Ratio Sage Therapeutics, Inc|Capitalization to Book Value Ratio Synaptogenix, Inc|TRVN - Market Cap to Net Assets Ratio|Market Value to Book Value VIGL|Market Value to Book Value Ratio Anew Medical, Inc. (WENA)|Market Value to Book Value Ratio Cerevel Therapeutics Inc CERE